Global Age Related Macular Degeneration Market Growth & Demand 2031

Global age related macular degeneration market is projected to witness a CAGR of 9.6% during the forecast period 2024–2031, growing from USD 10.19 billion in 2023 to USD 21.22 billion in 2031F. The market witnessed significant growth in the recent years and is expected to further expand over the forecast period.

Age related macular degeneration (AMD) occur because of damage caused to macula due to aging. Macula is a part of retina, which is responsible for translating the light, that enters the eye, into images. It is responsible for central vision, allowing individuals to view objects directly in front of them. AMD is one of the leading causes of vision loss for older population. The different types of age related macular degeneration include dry AMD and wet AMD. Dry AMD occurs in three stages that include early, intermediate, and late. Wet AMD usually causes faster loss of vision, dry AMD can turn into wet AMD. It occurs due to abnormal blood vessel growth at the back of the eye, which causes damage to macula. According to an article published in Journal Cureus, in September 2022, it is estimated that 200 million people suffer from AMD. The number is projected to increase to roughly 300 million by 2040. The age related macular degeneration market growth can be attributed to the increased initiatives by various health agencies and NGOs across the globe to spread awareness about the adequate course of treatment and impact of the disease.

Increasing Investments by Market Players is Supporting Market Expansion

Owing to increasing prevalence of age-related macular degeneration in various regions across the globe, several market players and research institutions are investing towards the development of treatment options and early diagnostic solutions to combat the disease. For instance, Adverum Biotechnologies, Inc. is developing Ixoberogene soroparvovec (Ixo-vec) for the treatment of wet AMD. The clinical-stage gene therapy product candidate utilizes AAV.7m8, a propriety vector. Under the control of proprietary expression cassette, it carries an aflibercept coding sequence. Current care methods for wet AMD care require frequent anti-VEGF injections in the eyes, causing burden for both caregivers and patients. Adverum believes that Ixoberogene soroparvovec has the potential for providing cost effective, durable, and safe in-office treatment options that will address the requirements of retina specialists and healthcare systems across the globe as well as patients and their caregivers. The study conducted in patients demonstrated consistent and continuous therapeutic levels from Ixoberogene soroparvovec in study subjects with wet AMD.

Get Full Report with discount : https://www.marketsandata.com/industry-reports/age-related-macular-degeneration-market

Growing Prevalence in Aging Population to Boost the Market

The demand for AMD drugs is anticipated to increase over the forecast period, owing to rising aging population. As the risk for macular degeneration amongst the geriatric population is high, the market is expected to grow with the increasing number of older people. According to the World Health Organization, by 2030, 1 in 6 people living across the globe will age 60 and above. By 2050, the world’s population aged 60 and above will reach 2.1 billion and by 2050 the number of individuals aging 80 years or older will reach 426 million.

The Centers for Disease Control and Prevention projects that 7.3 million individuals in America are at a heightened risk of loss of vision from age related macular degeneration and 1.8 million people suffer from the disease. These factors are bolstering the growth of the macular degeneration treatment market.

North America to Hold a Significant Share of the Market

The growth of geriatric population, strong presence of several market players, and increasing cases of age-related macular degeneration is supporting the expansion of the market in the region. It is estimated that approximately 20 million adults in the United States suffer from some sort of macular degeneration. As per Canadian Ophthalmological Society, age related macular disorder is one of the leading causes of blindness in Canada and as of February 2022, affects approximately 2 million Canadians.

The society is dedicated towards spreading awareness about the different treatments by highlighting the research conducted by Canadian ophthalmologists that are dedicated towards innovating new therapies that aim at enhancing the treatment for wet AMD. Promising age-related macular degeneration research is being conducted on several fronts. Various chemical trials are underway with novel therapies that aim at enhancing the treatment options for AMD. Such continuous investments and initiatives towards development of therapies for age related macular degeneration are further supporting the expansion of North America age related macular degeneration market.

Wet AMD Anticipated to Hold Significant Market Share

Wet age-related macular degeneration roughly accounts for 10% of cases, however, it results in 90% of cases of legal blindness. This disease is an advanced form of the AMD condition and can cause severe and rapid loss of vision. It occurs due to abnormal growth of blood vessels at the back of the eye, causing damage to macula.

The current standard of care to aid the prevention of vision loss progression are anti-vascular endothelial growth factor (VEGF) therapies, however, these therapies require repeated intravitreal injections for the remainder of the patient’s life. The highly demanding treatment schedule that requires injections every four to twelve weeks is expected to add to the overall demand in the market. Recently, an ophthalmologist at Mayo Clinic in Minnesota, the United States, performed the first subretinal gene therapy as a potential one-time treatment for wet age related macular degeneration as part of a clinical study of RGX-314.

Age-related macular degeneration (AMD) is a progressive eye condition that affects millions of people worldwide, causing gradual loss of central vision and impacting daily activities such as reading, driving, and recognizing faces. As the aging population grows and the prevalence of AMD increases, the global market for AMD treatments and therapies is witnessing significant growth and innovation. In this blog post, we delve into the dynamics of the global age-related macular degeneration market, exploring key trends, treatment options, and future prospects.

Understanding Age-Related Macular Degeneration: Age-related macular degeneration is a degenerative eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. There are two main types of AMD: dry AMD, characterized by the gradual breakdown of retinal cells and the accumulation of drusen (yellow deposits), and wet AMD, marked by the growth of abnormal blood vessels beneath the retina, leading to leakage and scarring.

Market Trends:

1. Advances in Therapeutic Approaches: The global AMD market is witnessing rapid advancements in therapeutic approaches aimed at slowing disease progression and preserving vision. Treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections, which target abnormal blood vessel growth in wet AMD, as well as emerging therapies targeting inflammation, oxidative stress, and neuroprotection in both dry and wet AMD.
2. Personalized Medicine: With a growing emphasis on personalized medicine, researchers are exploring genetic and molecular biomarkers to tailor AMD treatments to individual patients. Genetic testing and biomarker analysis can help identify patients at higher risk of disease progression and guide treatment decisions, leading to more effective and personalized care strategies.
3. Combination Therapies: Combination therapies, involving the simultaneous or sequential administration of multiple treatment modalities, are gaining traction in the AMD market. Combining anti-VEGF therapy with other agents targeting different pathways implicated in AMD pathogenesis, such as complement inhibitors or neuroprotective agents, holds promise for synergistic effects and improved treatment outcomes.
4. Technological Innovations in Diagnosis and Monitoring: Technological innovations in imaging modalities, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF), are revolutionizing the diagnosis and monitoring of AMD. High-resolution imaging techniques enable clinicians to visualize retinal changes with unprecedented detail, facilitating early detection of AMD and more accurate assessment of treatment response.

Download Free Sample Report: https://www.marketsandata.com/industry-reports/age-related-macular-degeneration-market/sample-request

Growth Drivers:

1. Aging Population Demographics: The aging global population demographic is a primary driver of the AMD market, as age is the leading risk factor for the development of AMD. With life expectancy on the rise and the baby boomer generation reaching old age, the prevalence of AMD is expected to increase substantially, driving demand for AMD treatments and therapies.
2. Lifestyle Factors and Environmental Risk Factors: Lifestyle factors such as smoking, diet, and sunlight exposure, as well as environmental risk factors such as air pollution and oxidative stress, contribute to the development and progression of AMD. As awareness of modifiable risk factors grows and public health initiatives promote healthy aging practices, there is increasing demand for AMD prevention strategies and early intervention measures.
3. Healthcare Infrastructure and Access to Care: Access to quality eye care services, including regular eye examinations and timely diagnosis of AMD, is crucial for effective disease management. Investments in healthcare infrastructure, expansion of telemedicine and teleophthalmology services, and initiatives to improve eye care access in underserved communities are driving market growth and enhancing patient outcomes.

Future Outlook: The future of the global age-related macular degeneration market holds promise for continued innovation and progress in AMD treatment and management. With ongoing research efforts focused on deciphering the underlying mechanisms of AMD, identifying novel therapeutic targets, and developing more effective interventions, there is optimism for improved outcomes and quality of life for individuals affected by AMD.

New Developments in Eylea Injections

Eylea blocks the leakage of fluid caused by abnormal growth of blood vessels on the backside of the eye. In 2024, Molecular Therapeutics, linked their gene therapy to a reduction of wet AMD treatment burden by 90%, encouraging the organization to initiate planning for entry in phase 3 next year. An adeno-associated virus vector is used by 4D-150 for delivering transgenes encoding aflibercept. The aim is to eliminate the requirement for frequent injections of Eylea. In phase 2, 51 wet age-related macular degeneration patients at random, for eight weeks received injections of aflibercept or a shot of one of two doses of 4D-150. The patients on an average received 10 anti-VEGF injections in the previous year. By the twenty-four-week analysis, two-thirds of the patients that were on high dose, were injection free.

Future Market Scenario (2024–2031F)

Researchers from Anglia Ruskin University (ARU), have been working on developing a way to grow healthy retinal pigment epithelial (RPE) cells that can remain viable for up to 150 days. Retinal pigment epithelial cells are present outside the neural part of retina. The replacement of retinal pigment epithelial cells is one of the various promising therapeutic options available for effective treatment of age-related macular degeneration. Researchers are actively working on finding effective ways for transplanting these cells in eyes.

Recently Adverum Biotechnologies, Inc. released data from their optic extension study on patients suffering from wet age-related macular degeneration during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) annual meeting. The patients continued to experience long term benefits including reduction in anti-VEGF treatment burden and maintenance of vision.

Conclusion: The global age-related macular degeneration market is a dynamic and evolving landscape, characterized by advances in therapeutic approaches, technological innovations, and a growing emphasis on personalized medicine. As the prevalence of AMD continues to rise alongside demographic shifts and changing lifestyle patterns, the need for effective AMD treatments and interventions becomes increasingly pressing. With concerted efforts from researchers, healthcare providers, and industry stakeholders, the vision of a world where AMD is effectively prevented, diagnosed, and managed is within reach, offering hope to millions of individuals affected by this sight-threatening condition.

Contact

Mr. Vivek Gupta

5741 Cleveland street, 

Suite 120, VA beach, VA, USA 23462

Tel: +1 (757) 343–3258

Email: [email protected]

Website: https://www.marketsandata.com